LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Merck & Company today. The company’s shares opened today at $83.96. Elevate Your Investing Strategy: T ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will increase.

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet medical needs. | Omega Funds has raised $647 million for the investment shop ...